Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells.
Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.
Company Details
- Employees
- 190
- Founded
- -
- Address
- 700 Klein Road, Plano,tx 75074,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.oranomed.com
- HQ
- Plano, TX
Orano Med Questions
Orano Med's website is http://www.oranomed.com
Orano Med's LinkedIn profile is https://www.linkedin.com/company/orano-med
Orano Med has
190 employees.
View email and phone details for 190
employees at Orano Med.
Orano Med's industry is
Biotechnology Research
Orano Med's top competitors are
Forbion,
Inventiva,
Radiomedix, Inc.,
Longboard Pharmaceuticals,
Chengdu Baiyu Pharmaceutical,
Orano,
Sanofi,
Aktis Oncology,
Sage Therapeutics,
Naya Therapeutics.
Orano Med's categories are Biotechnology Research
Orano Med's founding year is 2009
